U.S. markets close in 55 minutes
  • S&P 500

    3,892.46
    -19.28 (-0.49%)
     
  • Dow 30

    31,369.96
    -130.72 (-0.41%)
     
  • Nasdaq

    11,506.51
    -101.11 (-0.87%)
     
  • Russell 2000

    1,778.29
    +12.55 (+0.71%)
     
  • Crude Oil

    109.32
    +1.70 (+1.58%)
     
  • Gold

    1,825.10
    -5.20 (-0.28%)
     
  • Silver

    21.14
    +0.01 (+0.07%)
     
  • EUR/USD

    1.0583
    +0.0025 (+0.23%)
     
  • 10-Yr Bond

    3.2000
    +0.0750 (+2.40%)
     
  • GBP/USD

    1.2272
    +0.0002 (+0.02%)
     
  • USD/JPY

    135.4300
    +0.2600 (+0.19%)
     
  • BTC-USD

    20,817.94
    -380.46 (-1.79%)
     
  • CMC Crypto 200

    453.87
    -7.93 (-1.72%)
     
  • FTSE 100

    7,258.32
    +49.51 (+0.69%)
     
  • Nikkei 225

    26,871.27
    +379.30 (+1.43%)
     

The B.R.A.I.N. Biotechnology Research and Information Network (ETR:BNN) Share Price Is Down 46% So Some Shareholders Are Getting Worried

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

B.R.A.I.N. Biotechnology Research and Information Network AG (ETR:BNN) shareholders will doubtless be very grateful to see the share price up 54% in the last month. But that doesn't help the fact that the three year return is less impressive. In fact, the share price is down 46% in the last three years, falling well short of the market return.

Check out our latest analysis for B.R.A.I.N. Biotechnology Research and Information Network

B.R.A.I.N. Biotechnology Research and Information Network isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.

In the last three years, B.R.A.I.N. Biotechnology Research and Information Network saw its revenue grow by 19% per year, compound. That's a fairly respectable growth rate. Shareholders have endured a share price decline of 19% per year. This implies the market had higher expectations of B.R.A.I.N. Biotechnology Research and Information Network. However, that's in the past now, and it's the future is more important - and the future looks brighter (based on revenue, anyway).

The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).

XTRA:BNN Income Statement May 4th 2020
XTRA:BNN Income Statement May 4th 2020

If you are thinking of buying or selling B.R.A.I.N. Biotechnology Research and Information Network stock, you should check out this FREE detailed report on its balance sheet.

A Different Perspective

B.R.A.I.N. Biotechnology Research and Information Network shareholders may not have made money over the last year, but their total loss of 6.2% isn't as bad as the market loss of around 6.2%. Furthermore, the stock lost shareholders 19% per year over three years, so the one-year return was better in a relative sense. It is of course not much comfort to know that the losses have slowed. Shareholders will be hoping for a proper turnaround, no doubt. It's always interesting to track share price performance over the longer term. But to understand B.R.A.I.N. Biotechnology Research and Information Network better, we need to consider many other factors. Take risks, for example - B.R.A.I.N. Biotechnology Research and Information Network has 1 warning sign we think you should be aware of.

Of course B.R.A.I.N. Biotechnology Research and Information Network may not be the best stock to buy. So you may wish to see this free collection of growth stocks.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on DE exchanges.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.